Vemurafenib (PLX4032 or RG7204) was kindly donated by Roche for study purpose. Vemurafenib was dissolved in DMSO to a stock concentration of 1 mg/ml. The Vemurafenib stock was freshly diluted before each experiment to 60 μg/ml unless stated otherwise. Dabrafenib and trametinib were obtained from Alsachim (Illkirch-Graffenstaden, France). Both drugs were diluted freshly to 90 and 12 ng/ml, respectively.
Trametinib
Manufactured by Alsachim
Sourced in France
Trametinib is a chemical compound used as a laboratory reagent. It functions as a selective inhibitor of the mitogen-activated protein kinase (MEK) enzymes MEK1 and MEK2.
Automatically generated - may contain errors
Lab products found in correlation
Dabrafenib, by Alsachim (2 mentions)
Vemurafenib, by Roche (1 mentions)
D4540, by Merck Group (1 mentions)
Crizotinib, by Merck Group (1 mentions)
Acetonitrile and formic acid, by Avantor (1 mentions)
Lorlatinib, by Merck Group (1 mentions)
Q pod, by Merck Group (1 mentions)
Methanol, by Merck Group (1 mentions)
Ammonium formate, by Merck Group (1 mentions)
3 protocols using trametinib
1
Dissolution and Dilution of BRAF Inhibitors
2
Trametinib administration protocol for in vivo study
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Trametinib (C3822, ALSACHIM) was dissolved in dimethyl sulfoxide (D4540; Sigma-Aldrich) to a concentration of 10 mM ( 6.15 mg/mL) and kept in aliquots at -80°C until use. On treatment day, an aliquot of working solution was thawed and added to sterile PBS for gavage. dimethyl sulfoxide was added to PBS for the vehicle treatment. Trametinib was administered daily over the course of 2 weeks (days 1-15 post-RT) at a concentration of 1 mg/kg body weight by oral gavage in 200 μL of total volume.
3
Quantification of Oncology Drugs in Plasma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The reference materials for alectinib, alectinib M4, AZ5104 (osimertinib active metabolite), Crizotinib-13C2D5, imatinib, imatinib-D8, and osimertinib were purchased from LGC Standards (Molsheim, France). Crizotinib, lorlatinib, methanol, and ammonium formate were obtained from Sigma-Aldrich (St-Quentin-Fallavier, France). Alectinib-D8, binimetinib, binimetinib-13CD4, cobimetinib, cobimetinib-13C6, dabrafenib, dabrafenib-D9, encorafenib, encorafenib-13C2D3, osimertinib-13CD3, trametinib, and trametinib-13C6 were provided from Alsachim (Illkirch Graffenstaden, France). Acetonitrile and formic acid came from VWR. Ultra-pure water (18 MΩ) was produced via ultrafiltration with a Q-Pod (Millipore Corp., Molsheim, France). All chemicals were of analytical grade. Blank human plasma samples were provided by a local blood bank (EFS, Versailles, France) and stored at −20 °C until analysis.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!